Further research and prospective validation in dedicated studies are essential to comprehensively assess the impact of PIK3CA status and different CDK4/6 inhibitors on clinical outcomes in HR+/HER2- advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.